 Connection
James Burton to Antiviral Agents
This is a "connection" page, showing publications James Burton has written about Antiviral Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.269 |
|
|
|
-
Burton JR, Terrault NA, Goldberg DS, Bloom RD, Gilroy R, Heimbach JK, Brown RS, Everson GT, Rubin E, Wiesner R, Pomfret EA. Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation. Transplantation. 2020 03; 104(3):476-481.
Score: 0.469
-
Nordstrom EM, Biggins SW, Gralla J, Rosen HR, Everson GT, Burton JR. Consensus Interferon for Recurrent Hepatitis C Infection in Nonresponders to Peginterferon and Ribavirin After Liver Transplant. Exp Clin Transplant. 2015 Dec; 13(6):543-9.
Score: 0.349
-
Burton JR, Everson GT. HCV NS5B polymerase inhibitors. Clin Liver Dis. 2009 Aug; 13(3):453-65.
Score: 0.225
-
Burton JR, Klarquist J, Im K, Smyk-Pearson S, Golden-Mason L, Castelblanco N, Terrault N, Rosen HR. Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol. 2008 Sep; 49(3):329-38.
Score: 0.208
-
Terrault NA, Burton J, Ghobrial M, Verna E, Bayer J, Klein C, Victor D, Mohan S, Trotter J, Dodge J, Niemann CU, Rubin RA. Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors. Hepatology. 2021 06; 73(6):2110-2123.
Score: 0.125
-
O'Leary JG, Fontana RJ, Brown K, Burton JR, Firpi-Morell R, Muir A, O'Brien C, Rabinovitz M, Reddy R, Ryan R, Shprecher A, Villadiego S, Prabhakar A, Brown RS. Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. Transpl Int. 2017 Feb; 30(2):196-208.
Score: 0.094
-
Brown RS, O'Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JR, Stravitz RT, Durand C, Di Bisceglie AM, Kwo P, Frenette CT, Stewart TG, Nelson DR, Fried MW, Terrault NA. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016 Jan; 22(1):24-33.
Score: 0.088
-
Verna EC, Saxena V, Burton JR, O'Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation. 2015 Aug; 99(8):1644-51.
Score: 0.085
-
Wu LS, Rower JE, Burton JR, Anderson PL, Hammond KP, Baouchi-Mokrane F, Everson GT, Urban TJ, D'Argenio DZ, Kiser JJ. Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother. 2015 Apr; 59(4):2179-88.
Score: 0.082
-
Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Gordon F, Levitsky J, Terrault NA, Burton JR, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014 Dec 18; 371(25):2375-82.
Score: 0.081
-
Moorehead KJ, Burton JR, Everson GT, Zheng JH, Kerr BJ, Bushman LR, Wang M, Ju C, Nydam T, Kiser JJ. Intrahepatic antiviral quantification in a patient undergoing orthotopic cadaveric liver transplantation. J Antimicrob Chemother. 2015 Jan; 70(1):315-7.
Score: 0.080
-
Kiser JJ, Burton JR, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013 Oct; 10(10):596-606.
Score: 0.074
-
Burton JR, Everson GT. Management of the transplant recipient with chronic hepatitis C. Clin Liver Dis. 2013 Feb; 17(1):73-91.
Score: 0.072
-
Hammond KP, Wolfe P, Burton JR, Predhomme JA, Ellis CM, Ray ML, Bushman LR, Kiser JJ. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr. 2013 Jan 01; 62(1):67-73.
Score: 0.071
-
Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012 May; 55(5):1620-8.
Score: 0.068
-
Rosen HR, Weston SJ, Im K, Yang H, Burton JR, Erlich H, Klarquist J, Belle SH. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology. 2007 Aug; 46(2):350-8.
Score: 0.049
-
Arjal RR, Burton JR, Villamil F, Rosen HR. Review article: the treatment of hepatitis C virus recurrence after liver transplantation. Aliment Pharmacol Ther. 2007 Jul 15; 26(2):127-40.
Score: 0.049
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|